InsidersTradesSigma
Follow the STRATA Skin Sciences, Inc. stock price and the full directors' dealings record of the company, a publicly traded company based in United States. Shares are listed on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, STRATA Skin Sciences, Inc. has published 28 reports. Market capitalisation: €2k. The latest transaction was disclosed on 18 November 2025 (Cession). Among the most active insiders: Rubinstein Samuel. All data is free.
28
Insider Decl.
n/a
Thresholds
€212,688
13 ops.
Buy Volume
€6,545
2 ops.
Sell Volume
60Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 November 2025
Declarations28 total
5,500 shares@ US$1.328.5% of flowCommon StockSEC:0001051514-25-000016:0
19,100 shares@ US$3.14100.0% of flowCommon StockSEC:0001051514-24-000005:0
Canonical exit: 13 Oct 2024 (T+90)
230,573 shares@ €2.8803100.0% of flowCommon StockSEC:0001213900-24-062198:0
Canonical exit: 13 Oct 2024 (T+90)
230,573 shares@ €2.8803100.0% of flowCommon StockSEC:0001213900-24-062197:0
Canonical exit: 13 Oct 2024 (T+90)
14,338 shares@ US$0.44100.0% of flowSSKN Common StockSEC:0001051514-23-000070:0
Canonical exit: 29 Feb 2024 (T+90)
1,000 shares@ US$0.320.4% of flowCommon StockSEC:0001051514-23-000064:0
42,000 shares@ US$0.67435.1% of flowSSKN Common StockSEC:0001051514-23-000036:0
Canonical exit: 8 Nov 2023 (T+90)
5,151 shares@ US$0.6811.3% of flowSSKN Common StockSEC:0001051514-23-000038:0
Canonical exit: 8 Nov 2023 (T+90)
36,408 shares@ US$1.0341.9% of flowSSKN Common StockSEC:0001051514-23-000029:0
38,835 shares@ US$1.0347.4% of flowSSKN Common StockSEC:0001051514-23-000030:0
33,981 shares@ US$1.0379.4% of flowSSKN Common StockSEC:0001051514-23-000032:0
36,408 shares@ US$1.0379.4% of flowSSKN Common StockSEC:0001051514-23-000031:0
33,981 shares@ US$1.0348.1% of flowSSKN Common StockSEC:0001051514-23-000028:0
37,838 shares@ US$0.92549.9% of flowSSKN Common StockSEC:0001051514-22-000075:0
9,106 shares@ US$0.96120.6% of flowSSKN Common StockSEC:0001051514-22-000074:0
43,244 shares@ US$0.92549.1% of flowSSKN Common StockSEC:0001051514-22-000076:0
9,756 shares@ US$0.96120.6% of flowSSKN Common StockSEC:0001051514-22-000073:0
1,050 shares@ US$1.040.014% mcap100.0% of flowSSKN Common StockSEC:0001051514-22-000065:0
Canonical exit: 13 Sept 2022 (T+90)
23,131 shares@ US$1.120.34% mcap100.0% of flowSSKN Common StockSEC:0001051514-22-000057:0
Canonical exit: 10 Aug 2022 (T+90)
16,950 shares@ US$1.73360.36% mcap55.7% of flowSSKN Common StockSEC:0001051514-22-000035:0
Canonical exit: 23 Jun 2022 (T+90)
14,783 shares@ US$1.5820.29% mcap44.3% of flowSSKN Common StockSEC:0001051514-22-000033:0
Canonical exit: 22 Jun 2022 (T+90)
33,300 shares@ US$1.57350.64% mcap100.0% of flowSSKN Common StockSEC:0001051514-22-000032:0
Canonical exit: 22 Jun 2022 (T+90)
1,155 shares@ US$1.401.8% of flowSSKN Common StockSEC:0001051514-21-000064:0
Canonical exit: 6 Dec 2021 (T+90)
20,000 shares0SSKN Common StockSEC:0001051514-21-000034:0
25 of 28 declarations
关于 STRATA Skin Sciences, Inc.
STRATA Skin Sciences, Inc. 是一家专注于皮肤病学的美国医疗技术公司，在美国纳斯达克市场上市。公司总部位于宾夕法尼亚州霍舍姆，为皮肤科医生及其患者提供针对慢性皮肤病的靶向治疗平台。其定位是利基医疗技术公司，而非广泛的制药公司，其商业模式结合了设备销售和来自其已安装设备利用率的经常性收入。 公司围绕准分子激光技术发展，随后通过投资组合重塑和收购进一步聚焦。STRATA 放弃了其之前的 MelaFind 项目，并于 2016 年更名。如今，其核心商业产品包括 XTRAC® 和 Pharos® 准分子激光器以及 VTRAC® 灯系统，用于治疗牛皮癣、白癜风和其他炎症性或自身免疫性皮肤病。2022 年，STRATA 通过收购 TheraClear® 痤疮治疗系统（以 TheraClear® X 的名义销售）拓展了其战略，使公司也涉足痤疮治疗市场。 从竞争角度来看，STRATA 通过高度靶向的 UVB 光治疗技术脱颖而出，这些技术针对庞大但往往服务不足的皮肤病适应症。公司报告称，其在皮肤科诊所拥有已安装的系统，主要在美国，同时国际业务规模较小但不断增长。其经济效益由经常性治疗收入驱动，这比纯设备销售模式更具稳定性。 近期发展表明公司仍处于运营重建和扩张阶段。2025 年，STRATA 报告称季度收入适度增长，国际势头持续，并且在美国扩大炎症性和自身免疫性皮肤病的 CPT 报销代码方面取得进展，这可能增加其可寻址市场。公司还在墨西哥获得了 TheraClearX 的监管批准，并开始在该国进行首次商业部署。与此同时，近期美国证券交易委员会 (SEC) 的备案文件显示，其普通股已于 2026 年 2 月 19 日从纳斯达克资本市场退市，目前在场外交易 (OTC)，这是投资者评估流动性和融资风险时需要考虑的重要因素。 对于法国、比利时和瑞士投资者而言，STRATA 是一家美国医疗保健小型股公司，面临临床采用和报销范围扩大的双重影响。该股票应被视为高风险、高波动性的医疗技术股，其进展取决于商业化执行、支付方覆盖范围的扩大以及资产负债表的支撑。
